Sodium-glucose linked transporter 2 inhibitors reduce serum uric acid in type 2 diabetic mellitus patients with early nephropathy
ObjectiveTo explore the reducing serum uric acid (SUA) effects of dapagliflozin, a sodium-glucose linked transporter 2 (SGLT2) inhibitor in patients with type 2 diabetes mellitus (T2DM) with early nephropathy and hyperuricemia. MethodsSixty-five patients with early T2 diabetic nephropathy and hyperu...
Gorde:
| Egile Nagusiak: | , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Chinês |
| Argitaratua: |
The editorial office of the Journal of Internal Medicine Concepts & Practice
2025-12-01
|
| Saila: | Neike lilun yu shijian |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.16138/j.1673-6087.2025.05.04 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|